| | |  | | | | Record from Web of Science® | | | | | | |
| Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years |
|
|
| Author(s): Rousselot P (Rousselot, Philippe), Huguet F (Huguet, Francoise), Rea D (Rea, Delphine), Legros L (Legros, Laurence), Cayuela JM (Cayuela, Jean Michel), Maarek O (Maarek, Odile), Blanchet O (Blanchet, Odile), Marit G (Marit, Gerald), Gluckman E (Gluckman, Eliane), Reiffers J (Reiffers, Josy), Gardembas M (Gardembas, Martine), Mahon FX (Mahon, Francois-Xavier) |
| Source: BLOOD Volume: 109 Issue: 1 Pages: 58-60 Published: JAN 1 2007 |
| Times Cited: 86 References: 9 |
| Abstract: In the present study, we address the issue of the discontinuation of imatinib mesylate (Gleevec) in chronic myelogenous leukemia with undetectable residual disease for more than 2 years. Twelve patients were included. The median duration of real-time quantitative-polymerase chain reaction (RTQ-PCR) negativity and imatinib therapy were, respectively, 32 months (range, 24-46 months) and 45 months (range, 32-56 months) before imatinib interruption. Six patients displayed a molecular relapse with a detectable BCR-ABL transcript at 1, 1, 2, 3, 4, and 5 months. Imatinib was then reintroduced and led to a novel molecular response in most patients. Six other patients (50%) still have an undetectable level of BCR-ABL transcript after a median follow-up of 18 months (range, 9-24 months). We hypothesize that relapses observed within 6 months reflect the kinetics of undetectable dividing chronic myelogenous leukemia (CML) cells. Those cells may be eradicated or controlled in long-term nonrelapsing patients, as described in our study. |
| Document Type: Article |
| Language: English |
| Reprint Address: Mahon, FX (reprint author), Univ Bordeaux 2, Lab Hematopiese Normal & Leucem, INSERM, 146 Rue Leo Saignat,E217, F-33076 Bordeaux, France |
Addresses:
1. Univ Bordeaux 2, Lab Hematopiese Normal & Leucem, INSERM, F-33076 Bordeaux, France
2. Hop St Louis, Federat Hematol, Paris, France
3. Hop St Louis, Ctr Invest Clin, Paris, France
4. Hop Mignot, Serv Hematol & Oncol, Versailles, France
5. Hop Purpan, Hematol Serv, Toulouse, France
6. Hop Larchet, Hematol Serv, Nice, France
7. Hosp St Louis, INSERM, U728, Cent Hematol Lab, Paris, France
8. CHU Angers, Hematol Lab, Angers, France
9. CHU Haut Leveque, Serv Malad Sang, Pessac, France
10. Inst Bergonie, Bordeaux, France
11. CHU Angers, Hematol Serv, Angers, France |
| Publisher: AMER SOC HEMATOLOGY, 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA |
| Subject Category: Hematology |
| IDS Number: 121JM |
| ISSN: 0006-4971 |
| DOI: 10.1182/blood-2006-03-011239 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |